<DOC>
	<DOCNO>NCT01152996</DOCNO>
	<brief_summary>The purpose study determine long-term safety tolerability vortioxetine , daily ( QD ) , participant major depressive disorder .</brief_summary>
	<brief_title>Safety Tolerability Vortioxetine ( LuAA21004 ) - Open Label Extension Study</brief_title>
	<detailed_description>Depression recognize chronic illness imposes significant burden individual , family society . Major depressive disorder ( MDD ) among important cause disability worldwide , develop developed country . Major depressive disorder report common mood disorder , lifetime prevalence 15 % high 25 % woman . Major depressive disorder characterize presence 1 major depressive episode present depress mood , loss interest pleasure , disturbed sleep appetite , low energy , feeling guilt low self-worth , poor concentration . This multicenter extension study design allow eligible patient complete short-term efficacy safety study LuAA21004_315 ( NCT01153009 ) , LuAA21004_316 ( NCT01163266 ) LuAA21004_317 ( NCT01179516 ) receive 52-week treatment vortioxetine open-label extension study . Participants expect return site approximately 13 visit . A safety follow-up call make 4 week completion 52-week treatment period .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Has complete either study LuAA21004_315 ( NCT01153009 ) , LuAA21004_316 ( NCT01163266 ) , LuAA21004_317 ( NCT01179516 ) immediately prior enrollment extension study ( ie , baseline visit visit Week 8 [ Lu AA21004_317 ] Week 10 [ Lu AA21004_315 Lu AA21004_316 ] assessment precede protocol ) . Suffers recurrent major depressive episode ) primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion ( classification code 296.3x ) entry prior study . Twelvemonth continuation treatment Lu AA21004 indicate treatment participant accord opinion investigator . Females childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception throughout duration study . Has Major Depressive Disorder psychiatric disorder ( mania , bipolar disorder , schizophrenia , psychotic disorder ) diagnose prior study . In investigator 's clinical judgment , significant risk suicide and/or score ≥5 point item 10 ( suicidal thought ) Montgomery Åsberg Depression Rating Scale ( MADRS ) . In opinion investigator , unlikely comply clinical study protocol unsuitable reason . Has clinically significant moderate severe ongoing adverse event relate study medication prior study . Has used/uses disallow concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Depression</keyword>
	<keyword>Melancholia</keyword>
	<keyword>Paraphrenia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>